Skip to main content



HF Cohort

Due to safety concerns associated with some mask-based therapies for patients with heart failure and reduced left ventricular ejection fraction (LVEF), post-hoc analysis was performed on the heart failure cohort from the Pivotal Trial.

Patients with both heart failure and central sleep apnea comprise over half (68%) of patients studied in the remedē® System Pilot and Pivotal studies. In post-hoc analysis, the heart failure cohort demonstrated similar sleep and quality of life improvements to that of the full population.1,2

96% reduction in Central Apnea Index at 12 months
67% reduction in Apnea-Hypopnea Index at 12 months
15% relative improvement at LVEF at 12 months
34% relative improvement in MLHFQ at 12 months
Hospitalization chart
Cardiovascular mortality chart